Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

Judith Pratt, Catherine Winchester, Neil Dawson, Brian Morris

Research output: Contribution to journalLiterature review

95 Citations (Scopus)
18 Downloads (Pure)

Abstract

Although our knowledge of the pathophysiology of schizophrenia has
increased, treatments for this devastating illness remain inadequate. Here, we critically assess rodent models and behavioural end points used in schizophrenia drug discovery and discuss why these have not led to improved treatments. We provide a perspective on how new models, based on recent advances in the understanding of the genetics and neural circuitry underlying schizophrenia, can bridge the translational gap and lead to the development of more effective drugs. We conclude that previous serendipitous approaches should be replaced with rational strategies for drug discovery in integrated preclinical and clinical programmes. Validation of drug targets in disease-based models that are integrated with translationally relevant end point assessments will reduce the
current attrition rate in schizophrenia drug discovery and ultimately lead to therapies that tackle the disease process.
Original languageEnglish
Pages (from-to)560-579
Number of pages20
JournalNature Reviews Drug Discovery
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Drug Discovery
Rodentia
Schizophrenia
Pharmaceutical Preparations
Therapeutics

Keywords

  • disease models
  • translational medicine
  • schizophrenia
  • genetic models
  • drug discovery research
  • brain circuitry
  • animal
  • schizophrenia
  • drug discovery
  • rodent models
  • translational gap

Cite this

Pratt, Judith ; Winchester, Catherine ; Dawson, Neil ; Morris, Brian. / Advancing schizophrenia drug discovery : optimizing rodent models to bridge the translational gap. In: Nature Reviews Drug Discovery . 2012 ; Vol. 11, No. 7. pp. 560-579.
@article{593813423ade4d6dbfcc17cdd1d29382,
title = "Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap",
abstract = "Although our knowledge of the pathophysiology of schizophrenia hasincreased, treatments for this devastating illness remain inadequate. Here, we critically assess rodent models and behavioural end points used in schizophrenia drug discovery and discuss why these have not led to improved treatments. We provide a perspective on how new models, based on recent advances in the understanding of the genetics and neural circuitry underlying schizophrenia, can bridge the translational gap and lead to the development of more effective drugs. We conclude that previous serendipitous approaches should be replaced with rational strategies for drug discovery in integrated preclinical and clinical programmes. Validation of drug targets in disease-based models that are integrated with translationally relevant end point assessments will reduce thecurrent attrition rate in schizophrenia drug discovery and ultimately lead to therapies that tackle the disease process.",
keywords = "disease models, translational medicine, schizophrenia, genetic models, drug discovery research, brain circuitry, animal, schizophrenia , drug discovery , rodent models , translational gap",
author = "Judith Pratt and Catherine Winchester and Neil Dawson and Brian Morris",
year = "2012",
month = "7",
doi = "10.1038/nrd3649",
language = "English",
volume = "11",
pages = "560--579",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
number = "7",

}

Advancing schizophrenia drug discovery : optimizing rodent models to bridge the translational gap. / Pratt, Judith; Winchester, Catherine; Dawson, Neil; Morris, Brian.

In: Nature Reviews Drug Discovery , Vol. 11, No. 7, 07.2012, p. 560-579.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Advancing schizophrenia drug discovery

T2 - optimizing rodent models to bridge the translational gap

AU - Pratt, Judith

AU - Winchester, Catherine

AU - Dawson, Neil

AU - Morris, Brian

PY - 2012/7

Y1 - 2012/7

N2 - Although our knowledge of the pathophysiology of schizophrenia hasincreased, treatments for this devastating illness remain inadequate. Here, we critically assess rodent models and behavioural end points used in schizophrenia drug discovery and discuss why these have not led to improved treatments. We provide a perspective on how new models, based on recent advances in the understanding of the genetics and neural circuitry underlying schizophrenia, can bridge the translational gap and lead to the development of more effective drugs. We conclude that previous serendipitous approaches should be replaced with rational strategies for drug discovery in integrated preclinical and clinical programmes. Validation of drug targets in disease-based models that are integrated with translationally relevant end point assessments will reduce thecurrent attrition rate in schizophrenia drug discovery and ultimately lead to therapies that tackle the disease process.

AB - Although our knowledge of the pathophysiology of schizophrenia hasincreased, treatments for this devastating illness remain inadequate. Here, we critically assess rodent models and behavioural end points used in schizophrenia drug discovery and discuss why these have not led to improved treatments. We provide a perspective on how new models, based on recent advances in the understanding of the genetics and neural circuitry underlying schizophrenia, can bridge the translational gap and lead to the development of more effective drugs. We conclude that previous serendipitous approaches should be replaced with rational strategies for drug discovery in integrated preclinical and clinical programmes. Validation of drug targets in disease-based models that are integrated with translationally relevant end point assessments will reduce thecurrent attrition rate in schizophrenia drug discovery and ultimately lead to therapies that tackle the disease process.

KW - disease models

KW - translational medicine

KW - schizophrenia

KW - genetic models

KW - drug discovery research

KW - brain circuitry

KW - animal

KW - schizophrenia

KW - drug discovery

KW - rodent models

KW - translational gap

U2 - 10.1038/nrd3649

DO - 10.1038/nrd3649

M3 - Literature review

VL - 11

SP - 560

EP - 579

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 7

ER -